[{"id":"17de40db-c7f4-4c4a-854e-574167dd0b13","acronym":"APEAK","url":"https://clinicaltrials.gov/study/NCT06947811","created_at":"2025-06-07T14:40:16.432Z","updated_at":"2025-06-07T14:40:16.432Z","phase":"Phase 1/2","brief_title":"A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations","source_id_and_acronym":"NCT06947811 - APEAK","lead_sponsor":"Sun Yat-sen University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 06/09/2025","start_date":" 06/09/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-06-04"},{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"ed7a2006-5e7e-462b-a374-549a902e3ba9","acronym":"STX-478-101","url":"https://clinicaltrials.gov/study/NCT05768139","created_at":"2024-01-30T16:19:49.137Z","updated_at":"2025-02-25T13:41:27.084Z","phase":"Phase 1/2","brief_title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05768139 - STX-478-101","lead_sponsor":"Scorpion Therapeutics, Inc.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • tersolisib (LY4064809)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 04/17/2023","start_date":" 04/17/2023","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2029","study_completion_date":" 02/28/2029","last_update_posted":"2025-02-21"},{"id":"fb4d840f-ccf1-4e5e-ac00-2c10191c007e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554367","created_at":"2022-09-26T14:56:10.119Z","updated_at":"2025-02-25T13:54:43.263Z","phase":"Phase 2","brief_title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554367","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • RAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 08/26/2026","primary_completion_date":" 08/26/2026","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2025-02-20"},{"id":"accc8beb-5a40-4334-a4ae-f00e0d7cc772","acronym":"ELEVATE","url":"https://clinicaltrials.gov/study/NCT05563220","created_at":"2022-10-03T15:56:32.608Z","updated_at":"2025-02-25T14:17:18.649Z","phase":"Phase 1/2","brief_title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT05563220 - ELEVATE","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER • PIK3CA • CDK4","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 01/24/2023","start_date":" 01/24/2023","primary_txt":" Primary completion: 12/27/2026","primary_completion_date":" 12/27/2026","study_txt":" Completion: 12/28/2028","study_completion_date":" 12/28/2028","last_update_posted":"2025-02-18"},{"id":"38d96c78-7695-48ef-a4bd-d1c77b87723e","acronym":"NCI-2018-01050","url":"https://clinicaltrials.gov/study/NCT03774472","created_at":"2021-01-18T18:40:19.361Z","updated_at":"2025-02-25T14:15:17.560Z","phase":"Phase 1/2","brief_title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03774472 - NCI-2018-01050","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 04/17/2024","primary_completion_date":" 04/17/2024","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2025-02-17"},{"id":"d5e3296e-7887-47f7-a8e8-e85cdb5b5e2b","acronym":"MORPHEUS BC","url":"https://clinicaltrials.gov/study/NCT04802759","created_at":"2021-03-17T15:57:40.908Z","updated_at":"2025-02-25T12:28:00.493Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","source_id_and_acronym":"NCT04802759 - MORPHEUS BC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER • CDK4","pipe":" | ","alterations":" HER-2 positive • ER positive","tags":["ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-17"},{"id":"e36e7d0b-dea5-4fa8-afc8-fa11a5c8624f","acronym":"ASPIRE","url":"https://clinicaltrials.gov/study/NCT03691493","created_at":"2021-01-18T18:05:38.724Z","updated_at":"2025-02-25T14:07:17.394Z","phase":"Phase 2","brief_title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","source_id_and_acronym":"NCT03691493 - ASPIRE","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/08/2019","start_date":" 02/08/2019","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2025-02-17"},{"id":"63510ff8-29e3-41f2-bed7-9104cb9c93b1","acronym":"PALLAS","url":"https://clinicaltrials.gov/study/NCT02513394","created_at":"2021-01-17T17:11:10.182Z","updated_at":"2025-02-25T14:39:31.455Z","phase":"Phase 3","brief_title":"PALbociclib CoLlaborative Adjuvant Study","source_id_and_acronym":"NCT02513394 - PALLAS","lead_sponsor":"Alliance Foundation Trials, LLC.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5796","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-14"},{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"c5c6214b-5158-4684-8fe9-74226f7c6e70","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439735","created_at":"2021-01-18T16:57:58.769Z","updated_at":"2025-02-25T15:10:45.531Z","phase":"Phase 2","brief_title":"Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC","source_id_and_acronym":"NCT03439735","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-13"},{"id":"3d2a4107-6ea8-46a6-9838-84fd8db8b88b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02760030","created_at":"2021-01-18T13:32:06.217Z","updated_at":"2025-02-25T15:17:17.770Z","phase":"Phase 2","brief_title":"Endocrine Therapy Fulvestrant \u0026 Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02760030","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 02/16/2017","start_date":" 02/16/2017","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-12"},{"id":"59fe4335-1fcc-4358-b0b0-f40604168b4d","acronym":"HERKULES-3","url":"https://clinicaltrials.gov/study/NCT05039177","created_at":"2021-09-09T13:53:09.950Z","updated_at":"2025-02-25T15:19:15.517Z","phase":"Phase 1/2","brief_title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","source_id_and_acronym":"NCT05039177 - HERKULES-3","lead_sponsor":"Erasca, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-11"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"91232e9f-dbc4-40d6-b4a1-5da728f867c3","acronym":"KRYSTAL-16","url":"https://clinicaltrials.gov/study/NCT05178888","created_at":"2022-01-05T12:53:44.212Z","updated_at":"2025-02-25T15:27:11.129Z","phase":"Phase 1","brief_title":"Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)","source_id_and_acronym":"NCT05178888 - KRYSTAL-16","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Krazati (adagrasib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2025-02-11"},{"id":"e26f4832-18d8-4dd8-a4b0-bfc0f47b73b1","acronym":"VERITAC","url":"https://clinicaltrials.gov/study/NCT04072952","created_at":"2021-01-18T19:56:21.491Z","updated_at":"2025-02-25T15:26:10.187Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE®) in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04072952 - VERITAC","lead_sponsor":"Arvinas Estrogen Receptor, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • vepdegestrant (ARV-471)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 217","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 09/13/2024","primary_completion_date":" 09/13/2024","study_txt":" Completion: 03/13/2025","study_completion_date":" 03/13/2025","last_update_posted":"2025-02-11"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"08f4f7cb-1de9-4017-ba99-77f7d20628d0","acronym":"ARTS-021-1001","url":"https://clinicaltrials.gov/study/NCT05867251","created_at":"2023-05-19T13:05:01.323Z","updated_at":"2025-02-25T16:46:48.865Z","phase":"Phase 1/2","brief_title":"Study of AVZO-021 in Patients with Advanced Solid Tumors","source_id_and_acronym":"NCT05867251 - ARTS-021-1001","lead_sponsor":"Avenzo Therapeutics, Inc.","biomarkers":" HER-2 • CCNE1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/30/2023","start_date":" 08/30/2023","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-05"},{"id":"0d7fca80-0420-4ead-a6c7-20e34e32d1a2","acronym":"pionERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06065748","created_at":"2023-10-04T16:11:25.824Z","updated_at":"2025-02-25T16:47:04.424Z","phase":"Phase 3","brief_title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","source_id_and_acronym":"NCT06065748 - pionERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-05"},{"id":"93cce817-ed7e-442e-95cd-47f76d702a46","acronym":"","url":"https://clinicaltrials.gov/study/NCT02159755","created_at":"2021-01-18T10:03:07.008Z","updated_at":"2025-02-25T16:51:23.872Z","phase":"Phase 1","brief_title":"Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma","source_id_and_acronym":"NCT02159755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 06/25/2018","primary_completion_date":" 06/25/2018","study_txt":" Completion: 01/20/2026","study_completion_date":" 01/20/2026","last_update_posted":"2025-02-04"},{"id":"971ccbcc-807b-4f19-a719-95e21b179631","acronym":"C4551001","url":"https://clinicaltrials.gov/study/NCT04606446","created_at":"2021-01-19T20:31:32.792Z","updated_at":"2025-02-25T16:53:21.614Z","phase":"Phase 1","brief_title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04606446 - C4551001","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER • CDKN2A","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 08/13/2025","primary_completion_date":" 08/13/2025","study_txt":" Completion: 03/07/2027","study_completion_date":" 03/07/2027","last_update_posted":"2025-02-04"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"}]